MUFG Americas’s Cardlytics CDLX Stock Holding History

MUFG Americas’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5	Closed	–	–	124
2022 Q3	$0	Buy	+5	New	+$712	﹤0.01%	886

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $122M AUM 11.49% 1-Year Est. Return

GEH

General Equity Holdings Brooklyn, New York $167M AUM 4.07% 1-Year Est. Return

ACM

Alua Capital Management New York $103M AUM 11.88% 1-Year Est. Return

MUFG Americas's CDLX Position: Q4 2022 in Review

MUFG Americas sold out of Cardlytics (CDLX) in Q4 2022, closing a stake of 5 shares.

MUFG Americas first reported a position in CDLX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 121 funds tracked by Wall St. Rank hold CDLX as of Q4 2022.

MUFG Americas reported no remaining Cardlytics position as of Q4 2022 after selling out during the quarter.
MUFG Americas sold 5 Cardlytics shares in Q4 2022.
MUFG Americas first reported a position in Cardlytics in Q3 2022 and held it in 1 quarter.
MUFG Americas's Cardlytics position peaked at $0 in Q3 2022.
121 funds tracked by Wall St. Rank held Cardlytics as of Q4 2022.

Based on MUFG Americas's 13F filing for Q4 2022.